Bibliography and Research of Gary Cohen, M.D.

PUBLICATIONS:

Cohen, G.A., Kafer, E., Marshall, P.: Well Marked Strains of Aspergillus for Tests of Environmental Mutagens: Identification of Induced Mitotic Recombination and Mutation. Mutations Research 38:141, 1976.
Cohen, G.A., Hamburger, R.N., O’Connor, R.D.: Safety and Efficacy of Human IgE Pentapeptide. Annals of Allergy 52:83, 1984.
Cohen, G.A.: Insect Sting Allergy. Cutis 34:228, 1984
Cohen, G.A., O’Connor, R.D., MacPherson, G.A., Golembesky, H.A., Jalowayski, A.A.: Normal Nasal Cytology in Infancy. Annals of Allergy 54:112, 1985. Reprinted on Yearbook of Pediatrics, 1986 (Oski and Stockman), 191.
Cohen, G.A., Hamburger, R.N.: Anaphylaxis. Modern Medicine March: 117, 1985.
Cohen, G.A., Hartman, G., Hamburger, R.N., O’Connor, R.D.: Severe Anemia and Chronic Bronchitis Associated with a Markedly Elevated Specific IgG to Cow’s Milk Protein. Annals of Allergy 55:38, 1985.
Cohen, G.A., Berman, B.A.: Pulmonary Hemosiderosis. Cutis 35:106, 1985.
Berman, B.A., Cohen, G.A., Kniker, W.T.: An Allergist’s View of Atopic Dermatitis. Dermatologic Clinics 4(1):55, 1986.
Cohen, G.A., Hamburger, R.N.: “New and Promising Treatments” in Breneman, J.D.: Handbook on Food Allergies: Science and Technology, Marcek Dekker, Inc. New York, 1987.

ABSTRACTS:

Cohen, G.A., Hamburger, R.N.: Dose Response to Human IgE Pentapeptide (HEPP). Annals of Allergy, 50:351, 1983. (Presented to American College of Allergists and received Clemens von Pirquet Award for Allergy Research , New Orleans, 1983.)
Hamburger, R.N., Cohen, G.A., O’Connor, R.D.: Suppression of Atopic Allergic Symptoms, Skin Tests and Serum IgE Levels by Subcutaneous Injections of the Pentapeptide Asp-Ser-Asp-Pro-Arg in Man. Proc. 5th International Congress of Immunology, 1983.
Cohen, G.A., O’Connor, R.D., MacPherson, G.A., Golembesky, H.E., Jalowayski, A.A.: Normal Nasal Cytology in Infancy. (Presented to American Academy of Pediatrics, Scientific Session of the Allergy Section, San Francisco, 1983.)
Cohen, G.A., O’Connor, R.D., Hamburger, R.N., Culler, F., Curd, J.: Caesarian Section in a Patient with Hereditary Angioedema (HAE). Annals of Allergy 52:238, 1984. (Presented to American College of Allergists, San Francisco, 1984.)
Cohen, G.A., O’Connor, R.D., Hartman, G., Hamburger, R.N.: Severe Anemia with Chronic Bronchitis Associated with a Markedly Elevated Specific IgG to Cow’s Milk Protein (CMP). Annals of Allergy 52,233, 1984. (Presented to American College of Allergist, San Francisco, 1984.)
Prenner, B., Cohen, G.A., Sainz, C.: Preliminary Results of a Multicenter Study of the Antiallergy Pentapeptide “HEPP”. Annals of Allergy 52:240, 1984. (Presented to American College of Allergists, San Francisco, 1984.)
Cohen, G.A., Seltzer, J.S., Carson, S.H.: Response to Immuran in a child with Pulmonary Hemosiderosis and IgG 2 Deficiency. Annals of Allergy 62: 257, 1989. (Presented to American College of Allergists, Los Angeles, 1988.)
Cohen, G.A., : Anaphylaxis to Common Granola Cereal. Annals of Allergy 72:99, 1994. (Presented to American College of Allergists, Atlanta, 1993.)

PRESENTATIONS/LECTURES:

The following is a list of common topics that I have presented to Physician groups at various hospital grand rounds, staff meetings, and society meetings. I try to update this list on an annual basis and am always able to arrange lectures on specific topics that concern the medical staff, even if not listed.

ASTHMA
- Bronchial Hyperreactivity and Chronic Asthma
- Asthma as a Chronic Inflammatory Disease
- Asthma, Inflammation and Newer Approaches to Therapy
- Increasing Morbidity and Mortality in Chronic Asthma
- Emergency Treatment of Acute Asthma Exacerbations
- Inpatient Treatment of Hospitalized Asthmatics
- Exercise Induced Bronchospasm
- Infection-Related Asthma
- Food Allergies and Asthma
- Use of Steroids (oral, inhaled) in asthmatics
- Approaches to the Treatment of Nocturnal Asthma
ALLERGIC RHINITIS
- Newer Trends for the diagnosis and treatment of Rhinitis
- Sinusitis, chronic otitis and other complications of Rhinitis
- Inflammatory pathogenesis of Allergic Rhinitis and Treatment
- Nonsedating Antihistamines and their usage for chronic allergies
- Immunotherapy for Inhalant Allergen Disease
DERMATOLOGIC SKIN ALLERGIES
- Chronic Eczema: the role of food and aeroallergens
- Contact Dermatitis and Urticaria
- Acute and Chronic Urticaria: Approach to diagnosis & Treatment
- Recurrent Urticaria and Angioedema: A Frustrating Illness
- Hereditary Angioedema: Rare but Life-Threatening
FOOD ALLERGIES
- Food Allergies: Fact or Fiction
- Controversies regarding food allergies and multiple illnesses
- Food Allergies and Behavioral Issues: Is there a correlation?
- Food Allergies and Attention Deficit Disorder: What is real?
INSECT STING ALLERGY
- Insect Sting Allergy & Anaphylaxis
- Insect Sting Reactions: Who should see the Allergist?
- Reactions to Insect Bites & Stings
- Current Recommendations for Venom Immunotherapy
CLINICAL IMMUNOLOGY
- Evaluation of the patient with frequent respiratory infections
- Indications for the use of intravenous gammaglobulin
- Diagnosis of common immune deficiency disorders
ANAPHYLAXIS
- Differential Diagnosis & Treatment
- Evaluation of the patient with Exercise-Induced Anaphylaxis
- Drug-Vaccine Reactions and Anaphylaxis

NOTE: I would also be willing the speak on any other topic in the field of Allergy & Clinical Immunology.

PHYSICIAN’S LECTURES ON ABOVE TOPICS:

CHILDREN’S HOSPITAL – SAN DIEGO; GRAND ROUNDS
6/86; 2/87; 10/88; 7/92; 8/94;
MERCY HOSPITAL – SAN DIEGO; PEDIATRIC GRAND ROUNDS
11/86; 4/87; 6/88; 6/89; 1/91; 4/92; 12/93; 5/94; 3/95; INT. MED. GR. ROUNDS; 1/94; 3/95; 10/95;7/96
ALVARADO HOSPITAL MEDICAL CENTER – SAN DIEGO; GRAND ROUNDS
5/95;
SCRIPP’S HOSPITAL – LA JOLLA
PED. GR. ROUNDS – 7/96; 9/87; 3/88; 7/89; 5/94; 8/95;
FAM. PR. ROUNDS – 10/86; 8/88; 7/89; 11/90; 3/92; 9/93; 6/94; 6/95; 5/01
CAMP PENDLETON NAVAL HOSPITAL
MEDICAL GRAND ROUNDS – 2/89 FAMILY PRACTICE GRAND ROUNDS 4/99 PEDIATRIC GRAND ROUNDS 12/98, 9/99, 3/02, 7/03
NORTH COASTAL PEDIATRIC SOCIETY
PEDIATRIC GRAND ROUNDS – 5/91; 1/92; 7/96; 4/98; 8/02; 11/02; 6/03
SCRIPPS HOSPITAL – CHULA VISTA
PEDIATRIC GRAND ROUNDS – 5/93; 3/94; 5/95; 5/95; 4/98; 7/99
FAM. PR. GR. ROUNDS – 5/93; 3/94; 5/95; 7/96; 9/99; 10/02
SHARP MEMORIAL HOSPITAL – SAN DIEGO
MEDICAL GRAND ROUNDS – 6/88; 7/92
PARADISE VALLEY HOSPITAL
MEDICAL GRAND ROUNDS – 3/96
CORONADO HOSPITAL – CORONADO
MED. GR. ROUNDS – 7/86; 2/87; 5/88; 3/89; 11/93; 11/91; 3/92; 6/93; 11/94; 5/95; 11/95;
FAM. PR. ROUNDS – 8/89; 5/94;
INT. MED. ROUNDS – 12/90
SAN DIEGO OSTEOPATHIC SOCIETY – ANNUAL MEETING
GUEST SPEAKER – 7/89
HILLSIDE HOSPITAL – SAN DIEGO
MEDICAL GRAND ROUNDS – 9/88; 6/89
TRI CITY HOSPITAL – VISTA
PEDIATRIC GRAND ROUNDS – 9/89; 4/94; 5/95
INT. MED. GRAND ROUNDS – 5/94;
PALOMAR HOSPITAL – ESCONDIDO
PEDIATRIC GRAND ROUNDS – 7/88; 6/95;
POMERADO HOSPITAL – POWAY
MEDICAL GRAND ROUNDS – 5/86; 5/88; 5/93; 7/94; 6/95
U.C.S.D. MEDICAL CENTER – SAN DIEGO
ALLERGY ROUNDS – 8/86; 8/87; 10/87
PEDIATRIC CONFERENCES – 5/87; 10/87
PEDIATRIC GR. ROUNDS – 4/94;
CHILDREN’S HOSPITAL – ASTHMA SYMPOSIUM – 8/90
HUMANA SUNRISE HOSPITAL – LAS VEGAS, NEVADA
PEDIATRIC GRAND ROUNDS – 3/88; 11/94;
LAS VEGAS OSTEOPATHIC SOCIETY – ANNUAL MEETING
FEATURED SPEAKER – 7/89
VETERAN’S HOSPITAL – PHOENIX, ARIZONA
MEDICAL ROUNDS – 7/90
HUMANA HOSPITAL – PHOENIX, ARIZONA
MEDICAL GRAND ROUNDS – 7/90
MIRAMAR NAVAL BASE – SAN DIEGO
MEDICAL GRAND ROUNDS – 8/86; 4/87
GROSSMONT HOSPITAL – SAN DIEGO
PEDIATRIC GR. ROUNDS – 4/94; 3/95
MEDICAL GRAND ROUNDS – 4/94; 4/95;
SCRIPPS ENCINITAS – ENCINITAS
MEDICAL GRAND ROUNDS – 4/94;
SAN YSIDRO MEDICAL CLINIC – SAN YSIDRO
MEDICAL GRAND ROUNDS – 10/89; 6/90
LOS ROBLES HOSPITAL – THOUSAND OAKS
MEDICAL GRAND ROUNDS – 9/92
EASTERN IDAHO REGIONAL MEDICAL CENTER – IDAHO FALLS, IDAHO
MEDICAL GRAND ROUNDS – 2/94
ST. JOSEPHS HOSPITAL – BOSTON, MASSACHUSETTS
PEDIATRIC GRAND ROUNDS – 7/94
ST. ELIZABETHS HOSPITAL – BOSTON, MASSACHUSETTS
PEDIATRIC GRAND ROUNDS – 7/94
SAN FRANCISCO PULMONARY SOCIETY – SAN FRANCISCO, CALIFORNIA
LAFAYETTE PARK HOTEL
MEDICAL GRAND ROUNDS – 8/94
TERRELL MEDICAL SOCIETY – DALLAS, TEXAS
MEDICAL GRAND ROUNDS – 9/94

NOTE: 2005 Lecture Schedule presently being arranged. The simplest way for arranging a presentation for Medical staff is to contact me directly at our main office at (858) 271-1151.

I have also prepared and given numerous lectures & seminars to non-medical personnel including senior citizen groups, church and temple organizations, parent-teacher organizations, etc.

I have also given lectures to other medical personnel including hospital nursing staffs as well as the S.D. Unified School Nurses.

CLINICAL TRIALS:

TITLE: PHASE III STUDY OF THE EFFECTS OF ZILEUTON, 400 MG QID AND 600 MG QID, AND PLACEBO IN MODERATE ASTHMA

PROTOCOL M92-720

SPONSOR: ABBOTT LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: PHASE III STUDY OF THE EFFECTS OF ZILEUTON 600 MG QID IN PATIENTS WITH MODERATE ASTHMA COMPLETING PROTOCOL M-92-720

PROTOCOL M92-801

SPONSOR: ABBOTT LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: LONG TERM SURVEILLANCE STUDY OF ZILEUTON PLUS USUAL CARE VERSUS USUAL CARE IN PATIENTS WITH ASTHMA

PROTOCOL M94-199

SPONSOR: ABBOTT LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP COMPARISON OF FLUTICASONE PROPIONATE QUUEOUS NASAL SPRAY VERSUS ENCAPSULATED LORATADINE TABLETS VERSUS A COMBINATION OF FLUTICASONE AND LORATADINE VERSUS PLACEBO FOR TWO WEEKS IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS

PROTOCOL FLTA 4024

SPONSOR: GLAXO WELLCOME

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF LUTICASONE PROPIONATE AQUEOUS NASAL SPRAY VERSUS PLACEBO FOLLOWED BY A SIX MONTH OPEN LABEL SAFETY EXTENSION I N SUBJECTS WITH PERENNIAL NON-ALLERGIC RHINITIS

PORTOCOL FLTA 3010

SPONSOR: GLAXO WELLCOME

SUB-INVESTIGATOR: GARY A. COHEN,MD

TITLE: FORMOTEROL DRY POWDER (CGP-25827A) A TWELVE WEEK DOUBLE BLIND, PARALLEL GROUP TRIAL COMPARING THE SAFETY, TOLERABILITY AND EFFICACY OF FORMOTEROL DRY POWDER CAPSULES FOR INHALATION DELIVERED BY A SINGLE DOSE INHALER VERSUS ALBUTEROL METERED DOSE INHALER (MDI) VERSUS PLACEBO IN PATIENTS WITH MILD TO MODERATE ASTHMA

PROTOCOL 40

SPONSOR: CIBA-GEIGY CORPORATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, GROUP COMPARATIVE STUDY OF THE EFFICACY OF NEDOCROMIL SODIUM 0.5% NEBULIZER SOLUTION (TID) IN THE TREATMENT OF CHILDREN 5-11 YEARS OF AGE WITH BRONCHIAL ASTHMA

PROTOCOL 1241-3003

SPONSOR: FISONS CORPORATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, GROUP COMPARATIVE STUDY OF THE SAFETY AND EFFECTIVENESS OF NEDOCROMIL SODIUM (TILADE®) 4 MG QID VS PLACEBO ADMINISTERED VIA METERED DOSE INHALER (MDI)

PROTOCOL 1241-2338

SPONSOR: FISONS CORPORATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: OPEN LABEL MULTICENTER STUDY FO THE SAFETY OF NEDOCROMIL SOIDUM (TILADE®) 4 MG QID ADMINISTERED VIA METERED DOSE INHALER (MDI) IN THE MANAGEMENT OF BROHCHIAL ASTHMA IN CHILDREN

PROTOCOL 1231-2339

SPONSOR: FISONS CORPORATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: PILOT STUDY TO EVALUATE THE EFFICACY, TOLERABILITY AND SAFETY OF TWO DOSES OF HOE 1401 (ICATIBANT) IN COMPARISON TO PLACEBO IN THE TREATMENT OF BRONCHIAL ASTHMA

PROTOCOL LEV-USA-1

SPONSOR: HOESCHST-ROUSSEL PHARMACEUTICAL

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: PROTOCOL TO DETERMINE THE SAFETY AND EFFICACY OF LEVOCABASTINE NASAL SPRAY IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS, DOUBLE BLIND EVALUATION OF LEVOCABASTINE GIVEN FOUR TIMES A DAY, OR TWICE A DAY VS PLACEBO

PROTOCOL LEV-USA-1

SPONSOR: JANSSEN RESEARCH FOUNDATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF FIVE ORAL DOSES OF MK-0476 AND PLACEBO IN PATIENTS WITH STABLE, MODERATE ASTHMA

PROTOCOL 009-01

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: AN OPNE EXTENSION TO THE MK-0476 DOSE RANGING STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF MK-0476 IN PATIENTS WITH CHRONIC ASTHMA

PROTOCOL 009-11

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: AN OPEN EXTENSION TO THE MK-0476 DOSE RANGING STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF MK-0476 IN PATIENTS WITH CHRONIC ASTHMA

PROTOCOL 009-12

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF THREE ORAL DOSES OF MK-0476 AND PLACEBO IN ADULT PATIENTS WITH STABLE, MODERATE ASHTMA

PROTOCOL 025-01

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF MK-0476 AND PLACEBO IN PATIENTS WITH CHRONIC ASTHMA

PROTOCOL 031-01

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTOGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF MK-0476 TO PLACEBO IN PATIENTS WITH CHRONIC ASTHMA

PROTOCOL 031-02 OPEN LABEL EXTENSION

SPONOSR: MERCK RESEARCH LABORATORIES

SUB-INVESTOGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, TRIAL OF THE SAFETY AND EFFICACY OF ORAL BAYX1005 (100 MG BID VS 250 MG BID VS 500 MG BID VS PLACEBO FOR 6 WEEKS) IN PATIENTS WITH ASTHMA

PROTOCOL D93-024

SPONSOR: MILES, INC.

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARRALLEL GROUP FACTORIAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF VARIOUS DOSES OF ENALAPRIL ADMINISTERED CONCOMITANTLY WITH VARIOUS DOES OF LOSARTAN IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

PROTOCOL 157-00

SPONSOR: MERCK RESEARCH LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PLACEBO CONTROLLED DOUBLE BLIND, RANDOMIZED, PARALLEL STUDY COMPARING DURATION OF ACTION AND SAFETY AND EFFECTIVENESS OF FOUR DOSAGE STRENGTHS OF MDL 16,4551 IN THE TREATMENT OF SPRING ALLERGIES 1 & II PJPROO9 (I) & PFPROO10 (II)

PROTOCOL PJPROOO9

SPONSOR: MARION MERRELL DOW, INC.

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A TWELVE MONTH SAFETY TOLERANCE STUDY OF 240 MG MDL 16,455A QD AND PLACEBO QD IN NORMAL HEALTHY SUBJECTS

PROTOCOL 016455PR0027

SPONSOR: MARION MERRELL DOW, INC

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED SUDY OF THE EFFICACY AND SAFETY OF FOUR WEEKS TREATMENT WITH ORAL CP-80,633 IN ADULT PATIENTS WITH CHRONIC, MILD TO MODERATE ASTHMA

PROTOCOL 016455PR0027

SPONSOR: MARION MERRELL DOW, INC.

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PALCEBO CONTROLLED STUDY OF THE EFFICACY AND SAFAETY OF FOUR WEEKS TREATMENT WITH ORAL CP-80,633 IN ADULT PATIENTS WITH CHRINIC, MILT TO MODERATE ASTHMA

PROTOCOL 149-103-525

SPONSOR: PFIZER INC.

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A LONG TERM SAFETY STUDY OF SCH 32088 VS NASACORT® IN PERENNIAL RHINITIS

PROTOCOL C94-052-16

SPONSOR: SCHERING-PLOUGH RESEARCH INSTITUTE

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A STUDY FO THE EFFECTS OF INTRANASAL STEROIDS (BECLOMETHASONE DEIPROIONATE) ON THE GROWTH AND HPA AXIS FUNCTION OF CHILDREN

PROTOCOL C93-048-04

SPONSOR: SCHERING-PLOUGH RESEARCH INSTITUTE

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLEED TRIAL OF ZAFIRLUKAST (ACCOLATE) IN SUBJECTS WITH MILD TO MODERATE ASTHMA 3 WEEKS EFFICACY AND UP TO 52 WEEKS OPEN LABEL SAFETY EXTENSION

PROTOCOL 3788IL/0095

SPONSOR: ZENECA PHARMACEUTICALS

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, 13 WEEK TRIAL COMPARING TWO DOES OF ZAFIRLUKAST (ACCOLATE) IN COMBINATION WITH LOW-DOSE INHALED CORTICOSTEROIDS VS HIGH-DOSE CORTICOSTEROIDS ALONE IN SUBJECTS WITH MILD TO MODERATE ASTHMA

PROTOCOL 9188IL/0094

SPONSOR: ZENECA PHARMACEUTICALS

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP COMPARISON OF THE SAFETY AND EFFICACY OF TWO DOSES OF BAY X7195 AEROSOL WITH PALCEBO IN PATIENTS WITH ASTHMA

PROTOCOL D95-016

SPONSOR: BAYER CORPORATION

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: SAFETY AND EFFICACY OF ABT761 150 MG, 300 MG QD VS PLACBO IN PATIENTS WITH MODERATE ASTHMA, PIVOTAL NO.2

PROTOCOL M96-441

SPONSOR: ABBOTT LABORATORIES

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A LONG TERM OPEN LABEL, MULTICENTER STUDY OF ONCE DAILY ORAL SK & F 108566 IN PATIENTS WITH ESSENTIAL HYPERTENSION

PROTOCOL 050

SPONSOR: SMITHKLINE BEECHAM PAHRMACEUTICALS

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER TRIAL OF THE ANTIHYPERTENSIVE ACTIVITY AND SAFETY OF IRBESARTAN IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

PROTOCOL CV131-050

SPONSOR: BRISSTOL-MYERS SQUIBB

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: AN OPNE LABEL LONG-TERM TRAIL EVALUATING THE SAFETY OF BMS-180048 75 MG IN THE TREATMENTOF PATIENTS WITH MIGRAINE HEADACHE WITH OR WITHOUT AURA

PROTOCOL CN115-038

SPONSOR: BRISTOL-MYERS SQUIBB

SUB-INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLINE, PARRELLE GROUP, COMPARATIVE TRIAL EVALUATING FLUTICASONE PROPIONATE (220 MCG BID), TRIAMCINOLONE ACETONIDE (600 MCG BID), AND FLUTICASONE PROPIONATE (88MCG BID) IN COMBINATION WITH SALMETEROL XINAFOATE 42 MCG BID) EACH DELIVERED VIA A METERED DOSE INHALER, IN SUBJECTS WITH ASTHMA WHO REMAIN SYMPTOMATIC DESPITE RECEIVING INHALED CORTICOSTEROIDS

PROTOCOL FLTA 4022

SPONSOR: GLAXO WELLCOME

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOSE RANGING, SAFETY AND EFFICACY TRIAL WITH ZAFIRLUKAST (ACCOLATE®) IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH MILD TO MODERATE ASTHMA

PROTOCOL 9188IL/0139

SPONSOR: ZENECA PHARMACEUTICALS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, PARELLE GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG) VS ZFIRLUKAST (20 MG BID) IN SUBJECTS WHO ARE CURRENTLY RECEIVING BET AGONISTS ALONE

PROTOCOL FLTA 4030

SPONSOR: GLAXO WELLCOME

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: AN OPEN LABEL, MULTICENTER STUDY OF EFFICACY, SAFETY, AND EFFECT OF QOL OF ZYRTEC (CETIRIZINE HCI) SYRUP IN THE TREATMENTOF SEASONAL ALLERGIC RHINITIS IN CHILDREN

PROTOCOL L-0350

SPONSOR: PFIZER

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PLACEBO CONTROLLED DOSE RANGING STUDY OF MOMETASONE FUROATE HFA-227 METERED DOSE INHALER COMPARED TO BECLOMETHASONE DIPROPIONATE ( VANCERIL 84 MCG DOUBLE STRENGTH) IN THE TREATMENT OF ASTHMA IN SUBJECTS PREVIOUSLY MAINTAINED ON INHALED CORTICOSTEROIDS

PROTOCOL C97-222-08

SPONSOR: SCHERING-PLOUGH

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED EXPLORATORY SAFETY AND EFFICACY EVALUATION OF VP-63843 (PLECONARIL) IN THE TREATMENT OF EVTEROVIRAL UPPER RESPIRATORY TRACT DISEASE

PROTOCOL 843-010

SPONSOR: VIROPHARMA PAHRMACEUTICALS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOSE RANGING, SAFETY AND EFFICACY TRIAL OF ZAFIRLUKAST (ACCOLATE) IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH MILD TO MODERATE ASTHMA FOR 52 WEEKS

PROTOCOL 9188.0139 OPEN LABEL

SPONSOR: ZENECA PHARMACEUTICALS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, COMPARISON OF INHALED SALMETEROL XINAFOATE (42 MCG BID) WITH ORAL ZIFIRLUKAST (20 MG BID) IN SUBJECTS WITH MILD TO MODERATE ASTHMA

PROTOCOL SLGA5025

SPONSOR: SCHERING-PLOUGH

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A ONE YEAR OPEN LABEL SAFETY STUDY OF MOMETASONE FUROATE DRY POWDER INHALER MF DPI AND BECLOMETHASONE DIPROPIONATE (VANCERIL 84 MCG DOUBLE STRENGTH) IN CHILDREN WITH ASTHMA PREVIOUSLY MAINTAINED ON INHALED CORTICOSTEROIDS

PROTOCOL C970385

SPONSOR: SCHERING-PLOUGH

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PLACEBO CONTROLLED DOSE EFFICACY AND SAFETY STUDY OF MOMETASONE FUROATE DRY POWDER INHALER MF DPI IN THE TREATMENT OF ASTHMA IN CHILDREN PREVIOUSLY MAINTAINED ON BECLOMETHASONE DEPROPIONATE (VANCERIL 84 MCG DOUBLE STRENGTH)

PROTOCOL C97-380

SPONSOR: SCHERING-PLOUGH

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND CEFUROXIME AXETIL IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL CEF-97-003

SPONSOR: TAP HOLDINGS INC.

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL FOR SAFETY AND EFFICACY EVALUATION OF PLECONARIL IN THE TREATMENT OF VIRAL SYNDROME

PROTOCOL 843-020

SPONSOR: VIROPHARMA INC.

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG BID) VS MONTELUKAST DODIUM (10 MG QD) IN SUBJECTS WHO ARE RECEIVING BETA AGAONISTS ALONE

PROTOCOL FLTA4038

SPONSOR: GLAXO WELLCOME

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMEZED, DOUBLE BLIND, DOUBLE DUMMY, PARALLEL GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG BID) VS ZAFIRLUKAST (20 MG BID) IN ASTHMATIC SUBJECTS WHO ARE CURRENTLY RECEIVING LOW DOSE INHALED CORITCOSTEROIDS

PROTOCOL FLTA 4035

SPONSOR: GLAXO WELLCOME

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF TREATMENT OF SEASONAL ALLRGIC RHINITIS (sar) IN SUBJECTS WITH CO-MORBID ASTHMA AND A HISTORY OF SEASONAL EXACERBATIONS OF ASTHMA ON MEDICAL RESOURCES UTILIZATION FOR ASTHMA AND sar

PROTOCOL P97-293

SPONSOR: INTEGRATED THERAPTEUTICS GROUP, DIVISION OF SCHERING PLOUGH

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIDN, DOUBLE DUMMY, PARALLEL GROUP COMPARISON OF SALMETEROL XINAFOATE INHALATION POWDER (50MCG BID) WITH ORAL MONTELUKAST (10 MG QD) IN SUBJECTS WITH PERSISTENT ASTHMA SYMPTOMATIC ON CONCIMITANT INHALED CORTICOSTEROID THERAPY

PROTOCOL SMS40004

SPONSOR: GLAXO WELLCOME

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND CLARITHOMYCIN IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL CEF-97-005

SPONSOR: TAP HOLDINGS INC.

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND AMOXILILLIN/CLAVULANATE (AUGMENTIN) IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA

PROTOCOL CEF-97-006

SPONSOR: TAP HOLDINGS INC.

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, PARELLEL GROUP, OPEN LABEL, MULTICENTER CLINICAL STUDY COMPARING THE SAFETY, EFFICACY, QUALITY OF LIFE AND SOCIOECONIMIC VARIABLES OF TWICE DAILY FORMOTEROL POWDER (12 MG BID) TO TWICE DAILY SALMETEROL (50 MG BID) ADMINISTERED FOR SIX MONTHS TO ADULT SUBJECTS WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE (ROAD)

PROTOCOL FORADIL 073

SPONSOR: NOVARTIS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, COMPARATIVE STUDY OF CEFPROZIL VS CLARITHOMCIN IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL A1414.163

SPONSOR: BRISTOL-MYERS SQUIBB

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: EVALUATION OF THE SAFETY AND EFFICACY OF THREE ORAL DOSES OF ABT-773 IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL M99-048

SPONSOR: ABBOTT LABORATORIES

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL M00-216

SPONSOR: ABBOTT LABORATORIES

PRIMARY INVESTIGATOR: GARY A.COHEN, MD

TITLE: MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE SAFETY OF ZYRTEC SYRUP IN PEDIATRIC SUBJECTS 6 MOS. TO 11 MONTHS OF AGE

PROTOCOL A1431010

SPONSOR: PFIZER PHARMACEUTICALS GROUP

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: COMPARATIVE STUDY OF SAFETY OF ABT-492 100 MG QD, 200 MG QD, 400 MG QD, AND LEVOFLOXACIN 500 MG QD FOR THE TREATMENT OF SUBJECTS WITH ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS

PROTOCOL M01-298

SPONSOR: ABBOTT LABORATORIES

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED, LONG TERM GROWTH STUDY OF HFA FLUNISOLIDE IN CHILDREN WITH MILD ASTHMA

PROTOCOL ANC-MD-07

SPONSOR: ABBOTT LABORATORIES

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PHASE III DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER EFFICACY, SAFETY AND DOSE RESPONSIVE STUDY OF CICLESONIDE MDI 100 MCG/200 MCG/DAY AND 400 MCG/DAY ADMINISTERED DAILY FOR 12 WEEKS IN MODERATE PERSISTENT ASTHMA IN ADOLESCENTS AND ADULTS

PROTOCOL 321

SPONSOR: AVENTIS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: 12 WEEK TREATMENT WITH 250 MCG ROFLUMILAST VS PLACEBO IN PATIENTS WITH ASTHMA

PROTOCOL BY217/FK1 020

SPONSOR: ALTANA-BYK GULDEN

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, OPEN LABEL, LONG TERM 1 YEAR SAFETY STUDY OF CICLESONIDE 100 MCG DAILY, MDI ADMINISTERED ONCE DAILY FOR TREATMENT OF MILD TO MODERATE PERSISTENT ASTHMA IN ADOLSECENTS AND ADULTS

PROTOCOL XRP1526B-326

SPONSOR: AVENTIS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLINE, PARALLEL GROUP COMPARISON OF THE SAFETY AND EFFICACY OF THREE ONCE DAILY DOSES OF BAY 19-8004 WITH PALCEBO AND MONTELUKAST 10 MG DAILY IN PATIENTS WITH SYMPTOMIATIC ASTHMA

PROTOCOL BAY 19-8004

SPONSOR: BAYER PHARMACEUTICALS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, OPEN LABEL, RANDOMIZED, PARALLEL GROUP STUDY TO ASSESS THE LONG TERM SAFETY PERFORMANCE OF FEXOFENADINE COMPARED TO MONTELUKAST IN SUBJECTS WITH ASTHMA

PROTOCOL M016344P/3003

SPONSOR: BAYER PHARMACEUTICALS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF FEXOFENADINE 120 MG BID IN SUBJECTS WITH MILD TO MODERATE PERSISTENT ASTHMA

PROTOCOL M0164655P/3001

SPONSOR: AVENTIS

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: AN EFFICACY AND SAFETY STUDY OF LEVALBUTEROL, RACEMIC ALBUTEROL AND PLACEBO IN SUBJECTS TWELVE YEARS OF AGE AND OLDER WITH ASTHMA

PROTOCOL 051-353

SPONSOR: SEPRACOR

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL STUDY COMPARING THE EFFICACY AND SAFETY OF FEXOFENADINE 120 MG BID, FEXAOFENADINE 240 MG QD, AND PLACEBO IN SUBJECTS WITH PERENNIAL ALLERGIC RHINITIS

PROTOCOL M016455M/3002

SPONSOR: AVENTIS

PRIMARY INVESTIGATOR: GARY A. COHE, MD

TITLE: AN IN-USE STUDY OF THE DOSE INDICATOR FOR THE FLUNISOLIDE HFA INHALER SYSTEM REGULATORY PACKAGE

PROTOCOL ANC-MD-21

SPONSOR: FOREST

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PLACEBO CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY OF THE CURRENT US VERSION OF PULMICORT (BUDESONIDE) TURBUHALER AND THE NEW VERSION OF PULMICORT TURBUHALER IN ASTHMATIC ADULTS AND ADOLESCENTS CURRENTLY TREATED WITH INHALED STEROIDS

PROTOCOL SD-004-0620

SPONSOR: ASTRAZENECA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A PLACEBO CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY AND PHARMACOKINECTICS OF THE CURRENT US VERSION OF PULMICORT (BUDESNOIDE) TURBUHALER AND THE NEW VERSION OF PULMICORT TURBUHALER IN ASTHMATIC CHILDREN AND ADOLSECENTS

PROTOCOL SD-004-0726

SPONSOR: ASTRAZENECA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, BLINDED, MULTICENTER, PARALLEL STUDY COMPARING THE EFFICACY AND SAFETY OF PULMICORT RESUPLES (BEDESONIDE INHALATION SUSPENSION) AT 0.5 MG AD, 1.0 MG QD, 1.0 MG BID, 2.0 MG BID AND PULMICORT TURBUHALER (BUDESONIDE) AT 400 MCG BID IN ADOLSECENTS 12 YEARS OF AGE AND OLDER AND ADULTS WITH MODERATE TO SEVERE ASTHMA

PROTOCOL SD-004-0764

SPONSOR: ASTRAZENECA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, MULTICENTER, PLACEBO CONTROLLED PARALLEL GROUP S;TUDY OF FOUR MONTHS DURATION PER PATIENT TO EVALUATE THE SAFETY AND EFFICACY OF TREATMENT 24 MG BID AND 12 MG BID FORMOTEROL, DOUBLE BLIND AND 12 MG BID FORMOTEROL WITH ADDITIONAL ON DEMAND FORMOTEROL DOES, OPEN LABEL IN ADOLESCENT AND ADULT PATIENT WITH PERSISTENT STABLE ASTHMA

PROTOCOL CFOR258D52307

SPONSOR: NOVARTIS

PRIMARY INVESTOGATOR: GARY A. COHEN, MD

TITLE: A 24 WEEK, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ROFLUMILAST (250 ,CG OR 500 MCG) DAILY IN PATIENTS WITH ASTHMA

PROPTOCOL PDEAAS-1500-002

SPONSOR: PFIZER PHARMACIA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF ORAL ALMOTRIPTAN 6.25 MG, 12.5 MG, AND 25 MG IN THE ACUTE TREATMENT OF MIGRAINE IN ADOLSECENTS

PROTOCOL 638-CNS-0059-015

SPONSOR: PHARMACIA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD

TITLE: A 52 WEEK RANDOMIZED, DOUBLE BLIND, SIMGLE DUMMY, PARALLEL GROUP, MULTICENTER PHASE III STUDY COMPARING THE LONG TERM SAFETY OF SYMBICORT PMDI 160/4.5 MG X 4 ACTUATION TWICE DAILY TO SYMBICORT PMDI 160/4.5 MG X 2 ACTUATIONS TWICE DAILY AND BUDESONIDE HFA PMDI 160 MG X 4 ACTUATIONS TWICE DAILY IN ADULT AND ADOLESCENT SUBJECTS WITH ASTHMA

PROTOCOL SD-039-0728

SPONSOR: ASTRAZENECA

PRINCIPLE INVESTIGATOR: GARY A. COHEN, MD

TITLE: A RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED, PARALLEL GROUP, MULTICENTER, TWELVE WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF SYMBICORT PMDI 160/4.5 MCG (2 ACTUATIONS) ONCE DAILY (QD) COMPARED TO SYMBICORT PMDI 80/4.5 MCG (2 ACTUATIONS) QD, SYMBICORT PMDI 80/4.5 MCG (2 ACTUATIONS) BID AND TO BUDESONIDE PMDI 160 MCG (2 ACTUATIONS) QD IN ASTHMATIC SUBJECTS TWELVE YEARS OF AGE AND OLDER

PROTOCOL D5896C00001

SPONSOR: ASTRAZENECA

PRIMARY INVESTIGATOR: GARY A. COHEN, MD